Eton Licenses Late-Stage Topical Gel for Infantile Hemangiomas, Targets 2027 NDA
ETON has more than doubled off its 52-week low of $13.985.
Summary
Eton Pharmaceuticals has licensed U.S. rights to ASN-001, a late-stage topical gel for infantile hemangiomas, from Auson Pharmaceuticals. The product showed strong Phase II/III efficacy: 56% of patients achieved elimination or near-elimination of lesions at 24 weeks with twice-daily dosing, versus 15% on placebo. ASN-001 would be the first FDA-approved topical therapy for this indication, targeting an estimated 20,000–30,000 patients annually who currently use off-label ophthalmic timolol. The deal complements Eton's existing HEMANGEOL franchise, which addresses severe systemic cases, and leverages the same prescriber base. A bioavailability bridging study is planned, with an NDA submission expected in the second half of 2027. This follows a series of insider stock sales in recent months, but the acquisition adds a high-value pipeline asset with patent protection through 2044.
At the time of this announcement, ETON was trading at $46.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $13.99 to $50.18. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.